Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec;73:102415. doi: 10.1016/j.coph.2023.102415. Epub 2023 Dec 1.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and safety pro...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec 1;73:102415. doi: 10.1016/j.coph.2023.102415. Online ahead of print.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and sa...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec 1;73:102415. doi: 10.1016/j.coph.2023.102415. Online ahead of print.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and sa...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec 1;73:102415. doi: 10.1016/j.coph.2023.102415. Online ahead of print.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and sa...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec 1;73:102415. doi: 10.1016/j.coph.2023.102415. Online ahead of print.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and sa...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec 1;73:102415. doi: 10.1016/j.coph.2023.102415. Online ahead of print.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and sa...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Curr Opin Pharmacol. 2023 Dec 1;73:102415. doi: 10.1016/j.coph.2023.102415. Online ahead of print.ABSTRACTTranslating promising preclinical pain relief data for novel molecules from drug discovery to positive clinical trial outcomes is challenging. The angiotensin II type 2 (AT2) receptor is a clinically-validated target based upon positive proof-of-concept clinical trial data in patients with post-herpetic neuralgia. This trial was conducted because AT2 receptor antagonists evoked pain relief in rodent models of neuropathic pain. EMA401 was selected as the drug candidate based upon its suitable preclinical toxicity and sa...
Source: Current Opinion in Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Andrew J Shepherd Andrew Sc Rice Maree T Smith Source Type: research
Interventional functional diagnostics in gastrointestinal endoscopy: Combining diagnostic and therapeutic tools in the endoscopy suite with the functional lumen imaging probe
Curr Opin Pharmacol. 2023 Nov 28;73:102414. doi: 10.1016/j.coph.2023.102414. Online ahead of print.ABSTRACTWith technical progress of gastrointestinal functional testing, there has been a demand for more comprehensive examination of esophageal physiology and pathophysiology beyond high-resolution manometry. A new interventional technology based on impedance planimetry, the functional lumen imaging probe (FLIP), enables intraluminal measurement of distensibility and compliance of hollow organs. EndoFLIP uses balloon catheters to measure diameter and distension pressure to calculate cross-sectional area and distensibility in...
Source: Current Opinion in Pharmacology - November 29, 2023 Category: Drugs & Pharmacology Authors: Zuzana Vackova Ian Levenfus Daniel Pohl Source Type: research
Interventional functional diagnostics in gastrointestinal endoscopy: Combining diagnostic and therapeutic tools in the endoscopy suite with the functional lumen imaging probe
Curr Opin Pharmacol. 2023 Nov 28;73:102414. doi: 10.1016/j.coph.2023.102414. Online ahead of print.ABSTRACTWith technical progress of gastrointestinal functional testing, there has been a demand for more comprehensive examination of esophageal physiology and pathophysiology beyond high-resolution manometry. A new interventional technology based on impedance planimetry, the functional lumen imaging probe (FLIP), enables intraluminal measurement of distensibility and compliance of hollow organs. EndoFLIP uses balloon catheters to measure diameter and distension pressure to calculate cross-sectional area and distensibility in...
Source: Current Opinion in Pharmacology - November 29, 2023 Category: Drugs & Pharmacology Authors: Zuzana Vackova Ian Levenfus Daniel Pohl Source Type: research
